Skip to content
Search

Latest Stories

'No evidence vitamin D prevents Covid-19'

A new review by the National Institute for Health and Care Excellence (NICE) has concluded that there is no evidence to support taking vitamin D supplements to specifically prevent or treat Covid-19.

NICE, however, added that all people should continue to follow UK government advice on daily vitamin D supplementation to maintain musculoskeletal health during the pandemic.


The review comes after recent studies suggested that the high death rates among black, Asian and ethnic minority (BAME) populations could be related to vitamin D deficiency, due to the lack of the so-called ‘sunshine’ nutrient.

NICE examined five observational studies on vitamin D and Covid-19 published on or before June 18, 2020. All five of the studies were found to have a high risk of bias because of the low quality of evidence produced.

It said there was no data available from clinical trials on vitamin D supplementation for the prevention or treatment of Covid-19.

Paul Chrisp, a director at NICE said: "While there are health benefits associated with vitamin D, our rapid evidence summary did not identify sufficient evidence to support the use of vitamin D supplements for the treatment or prevention of Covid-19.

"We know that the research on this subject is ongoing, and Nice is continuing to monitor new published evidence."

Another rapid review by the Scientific Advisory Committee on Nutrition (SACN) found that current evidence does not support the use of vitamin D supplementation to prevent any infection of the sinuses, throat, airways or lungs.

The UK’s rates of vitamin D deficiency are among the highest in Europe.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less